Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2978629 | 1.00 | HSD17B10 (0.32) | HSD17B10KDM4EKMT2AL3MBTL1MAPT | |
| SCHEMBL4439934 | 1.00 | HSD17B10 (0.32) | HSD17B10KDM4EKMT2AL3MBTL1MAPT | |
| SCHEMBL2996212 | 1.00 | HSD17B10 (0.32) | HSD17B10KDM4EKMT2AL3MBTL1MAPT | |
| SCHEMBL2984003 | 1.00 | HSD17B10 (0.32) | HSD17B10KDM4EKMT2AL3MBTL1MAPT | |
| SCHEMBL4736439 | 1.00 | HSD17B10 (0.32) | HSD17B10KDM4EKMT2AL3MBTL1MAPT | |
| SCHEMBL2990050 | 0.83 | SMN1; SMN2 (0.39) | HSD17B10KDM4EKMT2AMAPT | |
| SCHEMBL2991430 | 0.83 | SMN1; SMN2 (0.39) | HSD17B10KDM4EKMT2AMAPT | |
| SCHEMBL5009651 | 0.83 | SMN1; SMN2 (0.39) | HSD17B10KDM4EKMT2AMAPT | |
| SCHEMBL2990977 | 0.83 | SMN1; SMN2 (0.39) | HSD17B10KDM4EKMT2AMAPT | |
| SCHEMBL2988145 | 0.83 | SMN1; SMN2 (0.39) | HSD17B10KDM4EKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214663-A1 | Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use | XENOPORT, INC. | 2008-09-04 | — | — | US | claimed |
| US-8324272-B2 | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use | XENOPORT, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100173992-A1 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-7709527-B2 | 2-acetyloxy-1-methylpropyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate; Parkinson's disease; crystalline forms; improved pharmacokinetics; oral administration | XENOPORT, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080214663-A1 | Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use | XENOPORT, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173992-A1 | LEVODOPA DIMETHYL-SUBSTITUTED DIESTER PRODRUGS, COMPOSITIONS, AND METHODS OF USE | COMT, DDT, DDC | HSD17B10 1818/4885KDM4E 1443/4885KMT2A 541/4885 |
| US-20080214663-A1 | Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use | COMT, DDT, DDC | HSD17B10 1783/4885KDM4E 1558/4885KMT2A 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.